This clinical trial focuses on the treatment of infectious endocarditis, a serious infection of the heart’s inner lining, often affecting the heart valves. The study aims to evaluate the safety and effectiveness of a shorter course of antibiotic treatment for this condition. Specifically, it targets infections caused by the bacteria Staphylococcus aureus, Enterococcus faecalis, or streptococci. The antibiotics being studied include Vancomycin, Meropenem, Ceftriaxone, Benzylpenicillin, Ampicillin, Cloxacillin, Cefotaxime, and Daptomycin. These medications are administered intravenously, meaning they are given directly into a vein.
The purpose of the study is to determine if a shorter treatment duration is as safe and effective as the standard longer treatment. Participants will receive one of the antibiotics or a combination, and some may receive a placebo. The study will monitor participants for six months to observe any outcomes such as death, septic embolization (a condition where infected particles travel through the bloodstream and block blood vessels), recurrence of the infection, or the need for heart surgery. Additionally, the study will look at hospital-related expenses, the length of hospital stay, the duration of antibiotic treatment, and any complications related to the intravenous administration of the drugs.
Participants will be closely monitored throughout the study period, which will last up to six months. The study will help determine if a shorter course of antibiotics can effectively treat infectious endocarditis, potentially leading to shorter hospital stays and reduced healthcare costs. This research is important for improving treatment strategies and outcomes for patients with this serious heart infection.
Sweden 